Efficacy and Safety of Pirfenidone for Mitigation of Interstitial Lung Abnormalities in COVID-19 Patients: A Meta-Analysis.

Can Respir J · 2026 · PMC12789973 · PMID 41522210

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

did not reach statistical significancep = 0.07so close (0.05 < p ≤ 0.1)

Pirfenidone therapy resulted in a trend toward reduced all‐cause mortality that did not reach statistical significance as compared to the control group (RR = 0.62; 95% CI: 0.37 to 1.03; p = 0.07) (Supporting Figure S6 ). 3.3.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.